Changes to the Shingles (zoster) vaccination program

From 1 November 2023, Shingrix®, a new recombinant zoster vaccine will replace ‘Zostavax®’ on the National Immunisation Program (NIP).
Shingrix® is a non-live vaccine and is highly effective in the prevention of herpes zoster and its complications, including post-herpetic neuralgia, in both immunocompetent and immunocompromised people. Shingrix® is funded as a 2-dose course for eligible people.


The recommendation for zoster vaccination has changed. A 2-dose course of Shingrix® is free for: o

  • Adults aged 65 years and over
  • Aboriginal and Torres Strait Islander adults aged 50 years and over
  • Immunocompromised adults aged 18 years and over with the following medical risk conditions: haemopoietic stem cell transplant
  • solid organ transplant
  • haematological malignancy
  • advanced or untreated HIV

Eligible people who have received one Shingrix® dose privately can receive their second dose free under the NIP provided they are 65 years of age and over. There is currently no recommendation for booster doses of Shingrix® vaccine.

If a patient has previously received Zostavax®, they cannot receive Shingrix® for free under the NIP until at least 5 years after the Zostavax® dose. The person will still need to complete the 2-dose schedule of Shingrix